title: Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost.
abstract: OBJECTIVE
  To evaluate the impact of age, glaucoma-specific diagnosis, and history of prior glaucoma surgery on outcomes in pediatric patients treated with latanoprost monotherapy.
  
  
  METHODS
  Prospective, randomized, double-masked 12-week, multicenter study included individuals 18 years or younger with glaucoma. Subjects stratified by age (0 to <3, 3 to <12, 12 to 18 y), diagnosis [primary congenital glaucoma (PCG) vs. non-PCG], and baseline intraocular pressure (IOP; 22 to <27, 27 to 31, >31 mm Hg), and randomized (1:1) to latanoprost vehicle (8 AM) and latanoprost 0.005% (8 PM) or timolol 0.5% (or 0.25% for those less than 3 y old; 8 AM/8 PM). IOP and safety assessments performed and adverse events recorded at baseline, weeks 1, 4, 12. Post hoc analyses in age-specific and diagnosis-specific groups of latanoprost-treated subjects were conducted (intent-to-treat population).
  
  
  RESULTS
  Sixty-eight subjects were treated with latanoprost (0 to <3, n=17; 3 to <12, n=26; 12 to 18, n=25); 82%, 42%, and 24%, respectively, had a primary diagnosis of PCG. Among Non-PCG subjects, 0% (0/3), 47% (7/15), and 63% (12/19) had a primary diagnosis of juvenile open-angle glaucoma in the 0 to <3, 3 to <12, and 12 to 18 year cohorts, respectively. Mean percent IOP reductions from baseline at week 12 were 22%, 24%, and 30% in the youngest through oldest age groups, respectively (P=0.3600). At week 12, a higher responder rate (≥15% IOP reduction) was observed in the non-PCG than in the PCG group (70% vs. 45%, respectively; P=0.0361). Latanoprost was well tolerated.
  
  
  CONCLUSIONS
  All age and diagnosis subgroups showed clinically relevant (>20%) mean IOP reduction at week 12 with latanoprost monotherapy.
authors.affiliation: *Pfizer Inc., New London, CT †Pfizer Inc., La Jolla, CA ‡Private Practice, Jupiter, FL §Pediatric Ophthalmology Department, University Hospital of Amiens, INSERM UMRS 968, France ∥Duke Eye Center, Durham, NC ¶NIHR Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, United Kingdom #Moran Eye Center, University of Utah, Salt Lake City, UT.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Maeda-Chubachi
authors.forename: Katherine
authors.initials: K
authors.lastname: Chi-Burris
authors.forename: Brad
authors.initials: B
authors.lastname: Simons
authors.forename: Dominique
authors.initials: D
authors.lastname: Brémond-Gignac
authors.forename: Sharon
authors.initials: S
authors.lastname: Freedman
authors.forename: Peng T
authors.initials: PT
authors.lastname: Khaw
authors.forename: Barbara
authors.initials: B
authors.lastname: Wirostko
authors.forename: Eric
authors.initials: E
authors.lastname: Yan
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D018463:Filtering Surgery / Q000706:statistics & numerical data*; D005902:Glaucoma, Open-Angle / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D006871:Hydrophthalmos / Q000175:diagnosis* / Q000188:drug therapy; D007223:Infant; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D013999:Timolol / Q000009:adverse effects / Q000627:therapeutic use; D014065:Tonometry, Ocular
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol